LONGEVITY HEALTH HLDGS
XAGELongevity Health Holdings, Inc. (XAGE) is a company focused on the development and commercialization of therapeutics aimed at extending healthy lifespan and addressing age-related diseases. It integrates advanced biotech research with innovative treatment approaches to promote longevity and improve overall health outcomes.
Company News
Longevity Health Holdings announced a merger with plasma collector true Health, causing its stock to surge over 115% on Tuesday. The all-stock transaction will continue trading under XAGE ticker and aims to leverage plasma synergies for bioaesthetic innovation.
Longevity Health Holdings (XAGE) announced a $59 million all-stock merger with THPlasma, a plasma collection company, expanding into the plasma industry and dropping a previous BioLabs deal. The merger is expected to close in Q4 2025 and provides significant growth potential.
Longevity Health Holdings has signed a definitive merger agreement with THPlasma, a plasma collection company, in an all-stock transaction. The merger is expected to close in Q4 2025 and will help address the US plasma shortage while providing growth opportunities for both companies.
Longevity Health Holdings (XAGE) announced that it has received a favorable decision from the Nasdaq Hearings Panel to continue its listing on Nasdaq, subject to the satisfaction of the Nasdaq initial listing rules for the combined company following the proposed merger with 20/20 BioLabs.
Halper Sadeh LLC is investigating several companies for potential violations of securities laws and breaches of fiduciary duties to shareholders, including Regulus Therapeutics, Kronos Bio, Longevity Health Holdings, and Southern States Bancshares.
